About Celleva Inc.
Pioneering regenerative medicine through exosome and DNA technologies
Celleva Inc. - Innovation in Regenerative Medicine
Celleva Inc. is a leading biotechnology company headquartered in South Korea, specializing in cutting-edge regenerative medicine. As the creator of both HELIXERA™ (advanced PN/PDRN technology) and PEXT™ (premium exosome therapy), Celleva delivers comprehensive solutions for cellular regeneration and aesthetic medicine.
Operating from state-of-the-art facilities in Goyang-si, Gyeonggi-do, Celleva combines breakthrough research in both exosome biology and DNA-based therapeutics with pharmaceutical-grade manufacturing to deliver world-class regenerative products.
Core Competencies:
- •Advanced exosome technology with Freshtracer™ quality system (PEXT)
- •Patented molecular weight optimization for PN/PDRN (HELIXERA)
- •GMP-certified production facilities for both product lines
- •International research collaborations and clinical validations
Dual Innovation: HELIXERA™ & PEXT™
HELIXERA™: Revolutionary PN/PDRN technology utilizing salmon DNA for advanced cellular regeneration and skin rejuvenation.
PEXT™: Premium exosome therapy products delivering cutting-edge solutions for regenerative medicine and aesthetic applications.
Years of Research
Scientific Publications
Countries Served